Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Karl Pummer(Medical University of Graz), G. Hubmer, H. Stettner, M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States))
PubMed
January 1, 1997
Cited by 51
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388
Clinical multidrug resistance in cancer: A multifactorial problem
|European Journal of Cancer|1996|178